New drug cocktail targets genetic weakness in Hard-to-Treat myeloma
NCT ID NCT06876142
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 39 times
Summary
This study tests two oral drugs, mirdametinib and sirolimus, together in people with a specific genetic form of multiple myeloma that has returned or not responded to treatment. The goal is to find a safe dose and see if the combination can shrink or control the cancer. About 54 adults with KRAS or NRAS gene changes will take the pills daily in 4-week cycles for up to a year, with long-term follow-up.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.